Overview

Mirtazapine in Alzheimer-associated Weight Loss

Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
Weight loss is a frequent problem associated with Alzheimers disease (AD). Mirtazapine has weight loss as a frequent side effect. The aim of this retrospective study is to check whether mirtazapine 30 mg (once daily) can counteract weight loss in patients with AD or mixed dementia (AD + vascular).
Details
Lead Sponsor:
Brugmann University Hospital
Treatments:
Mianserin
Mirtazapine